Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Rodney P RocconiMichael A Finan

Abstract

Considering the paucity of data relating erythropoiesis-stimulating agent (ESA) use to ovarian cancer survival, our objective was to evaluate the effect of ESA as used for the treatment of chemotherapy-induced anemia (CIA) on survival in ovarian cancer patients. A multi-institution retrospective chart review was performed on ovarian cancer patients. Data collection included patient demographic, surgicopathologic, chemotherapy, ESA, and survival data. Patients were stratified by ever-use of ESA and were compared using appropriate statistical methods. A total of 581 patients were eligible for analysis with 39% (n = 229) patients with ever-use of ESA (ESA-YES) and 61% (n = 352) never-use ESA (ESA-NO). Mean age was 60.4 years with most patients having stage IIIC (60%) of papillary serous histological diagnosis (64%) with an optimal cytoreduction (67%). Median follow-up for the cohort was 27 months. Both ESA-YES and ESA-NO groups were similar regarding age, body mass index, race, stage, histological diagnosis, and debulking status. Compared with the ESA-NO group, ESA-YES patients were significantly more likely to experience recurrence (56% vs 80%, P < 0.001) and death (46% vs 59%, P = 0.002). Kaplan-Meier curves demonstrated a signi...Continue Reading

References

Jul 25, 2003·British Journal of Haematology·Michael HedenusUNKNOWN Darbepoetin Alfa 20000161 Study Group
Aug 25, 2004·Cancer Treatment Reviews·Erminia FerrarioEmilio Bajetta
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian Leyland-JonesEls Vercammen
May 18, 2006·Journal of the National Cancer Institute·Julia BohliusAndreas Engert
Feb 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James R WrightMark N Levine
Oct 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Douglas RizzoUNKNOWN American Society of Hematology
May 2, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Marcello TonelliScott Klarenbach
Jun 19, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Zachary Crouch, Evelyn R Hermes DeSantis

❮ Previous
Next ❯

Citations

May 3, 2014·International Journal of Nanomedicine·Efthymia-Iliana MatthaiouYadollah Omidi
Oct 29, 2015·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Insiya B PoonawallaXianglin L Du

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.